ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
January 24 2024 - 4:05PM
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global
device, cell, and gene therapy-enabling company offering precise
navigation to the brain and spine, today announced installation and
completion of an initial procedure with both the ClearPoint Prism
Neuro Laser Therapy System and the ClearPoint Neuro Navigation
System by Dr. Jonathan Riley and team at Kaleida Health in Buffalo,
New York.
“We are ecstatic to have completed our first successful case
with combined ClearPoint Neuro MRI targeting and laser ablation
solutions,” stated Dr. Jonathan Riley, Assistant Professor of
Neurosurgery at the University of Buffalo, and Medical Director of
Functional Neurosurgery at Kaleida Health. “This is a world leading
suite of technologies that allows us to offer selected minimally
invasive neurosurgical procedures to patients in our region.”
“Our successful first case with Dr. Riley and the team at
Kaleida Health is emblematic of the excellent collaboration we have
both with our customers and within our organization,” said Chris
Osswald, Segment Leader for Laser Therapy at ClearPoint Neuro. “Our
limited market release has been such a positive experience, mainly
because of our team’s dedication. We look forward to continued
success together with the team at Kaleida Health and as we look to
expand into full market release later this year.”
The ClearPoint Prism Neuro Laser Therapy System features the
only non-cooled laser applicator on the market. ClearPoint’s
next-generation laser applicator technology eliminates the need for
external cooling, simplifying setup, reducing power and ablation
time, lessening imaging artifact, and enabling more efficient
workflows. The Prism laser is currently in limited market release
at select academic medical centers across the United States. For
more information about the ClearPoint Neuro Laser Therapy System
please visit:
https://www.clearpointneuro.com/clearpoint-prism-neuro-laser-system/
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling
company offering precise navigation to the brain and spine. The
Company uniquely provides both established clinical products as
well as pre-clinical development services for controlled drug and
device delivery. The Company’s flagship product, the ClearPoint
Neuro Navigation System, has FDA clearance and is CE-marked.
ClearPoint Neuro is engaged with healthcare and research centers in
North America, Europe, Asia, and South America. The Company is also
partnered with the most innovative pharmaceutical/biotech
companies, academic centers, and contract research organizations,
providing solutions for direct CNS delivery of therapeutics in
pre-clinical studies and clinical trials worldwide. To date,
thousands of procedures have been performed and supported by the
Company’s field-based clinical specialist team, which offers
support and services to our customers and partners worldwide. For
more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the context of the federal securities laws, including the Company’s
expectation for the future market of its products and services, and
other performance and results. These forward-looking statements are
based on management’s current expectations and are subject to the
risks inherent in the business, which may cause the Company's
actual results to differ materially from those expressed in or
implied by forward-looking statements. Particular uncertainties and
risks include those relating to: global and political instability,
supply chain disruptions, labor shortages, and macroeconomic and
inflationary conditions; future revenue from sales of the Company’s
products and services; the Company’s ability to market,
commercialize and achieve broader market acceptance for new
products and services offered by the Company; the ability of our
biologics and drug delivery partners to achieve commercial success,
including their use of the Company’s products and services in their
delivery of therapies; the Company’s expectations, projections and
estimates regarding expenses, future revenue, capital requirements,
and the availability of and the need for additional financing; the
Company’s ability to obtain additional funding to support its
research and development programs; the ability of the Company to
manage the growth of its business; the Company’s ability to attract
and retain its key employees; and risks inherent in the research,
development, and regulatory approval of new products. More detailed
information on these and additional factors that could affect the
Company’s actual results are described in the “Risk Factors”
section of the Company’s Annual Report on Form 10-K for the year
ended December 31, 2022, and the Company’s Quarterly Report on Form
10-Q for the three months ended September 30, 2023, both of which
have been filed with the Securities and Exchange Commission, and
the Company’s Annual Report on Form 10-K for the year ended
December 31, 2023, which the Company intends to file with the
Securities and Exchange Commission on or before March 31, 2024. The
Company does not assume any obligation to update these
forward-looking statements.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/66f919ac-c17e-402e-a88e-1211e8044e7c
Contact:
Media Contact:
Jacqueline Keller, Vice President of Marketing
(949) 900-6833
info@clearpointneuro.com
Investor Relations:
Danilo D’Alessandro, Chief Financial Officer
(888) 287-9109
ir@clearpointneuro.com
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From Apr 2023 to Apr 2024